A US review panel on July 23 recommended that compounding pharmacies be permitted to produce BPC-157, KPV, TB-500, and MOT-c. FDA career scientists opposed the move, citing insufficient safety and efficacy data. The recommendations are non-binding and the panel was scheduled to review three additional substances the following day.
No left-leaning sources covered this
“FDA panel supports access to peptides over objections by scientists at US regulator - Financial Times”
Read at Financial Times →No right-leaning sources covered this
The panel's recommendations represent a modest expansion of patient access to compounds sought for anti-inflammatory or tissue-repair effects, balanced against gaps in safety and efficacy data.
“Evidence-based regulation versus expanded access for chronic conditions”
The recommendations push back against excessive FDA controls and favor patient and physician choice in accessing naturally occurring substances.
“Limiting bureaucratic gatekeeping and centralized power”
The outcome highlights tension between individual medical autonomy and regulatory paternalism for endogenous compounds.
“Bodily sovereignty and informed consent over precaution”
All three prior perspectives accept natural occurrence as a safety signal and overlook compounding quality failures, panel influence, and missing surveillance mechanisms.
“Data threshold and enforcement history rather than access versus restriction”
Ratings by MBFC